Request a Quotation

Your Contact Information
Peptides Logo
Support and counselling under:
+49(0)3302 - 2022000 info@peptides.de
€0.00*




EBV LMP-2 419-427 (HLA-A*24:02)
( TYGPVFMCL )



Antigen Peptide EBV LMP-2 419-427 (HLA-A*24:02) TYGPVFMCL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

Sequence:TYGPVFMCL
Gene:LMP2
Delivery:1-3 days
C-Terminus:OH
N-Terminus:H
Amount:1 mg
Counter Ion:TFA
Protein:Latent membrane protein
Species:Epstein-Barr virus (EBV; Human herpesvirus 4)
Allele:HLA-A*24:02
Application :T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication :Infectious disease, Cancer, Neuroscience
Purity :95% HPLC-MS
Special references for this product will come soon.
For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >

€105.00*

Prices excl. VAT plus shipping costs

Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
Amount in mg
Product number: EP11157_1

More EBV LMP peptides
EBV LMP-1 125-133 (HLA-A*02:01) ( YLLEMLWRL )
Antigen Peptide EBV LMP-1 125-133 (HLA-A*02:01) YLLEMLWRL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP-2 340-349 (HLA-A*11:01) ( SSCSSCPLSK )
SSCSSCPLSK is a linear peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
EBV LMP-2 340-349 mutant (HLA-A*11:01) 348T ( SSCSSCPLTK )
SSCSSCPLTK is a linear mutated peptidic epitope (epitope ID60930) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assay

From €105.00*
Details
EBV LMP-2 419-427 (HLA-A*24:02) ( TYGPVFMCL )
Antigen Peptide EBV LMP-2 419-427 (HLA-A*24:02) TYGPVFMCL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP-2 426-434 (HLA-A*02:01) ( CLGGLLTMV )
EBV LMP-2 426-434 (HLA-A*02:01) CLGGLLTMV for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP1 159-167 (HLA-A*02:01) ( YLQQNWWTL )
Antigen Peptide EBV LMP1 159-167 (HLA-A*02:01) YLQQNWWTL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
EBV LMP2 131-139 (HLA-A*24:02) ( PYLFWLAAI )
Single peptide (PYLFWLAAI) for stimulation of human EBV LMP2(131-139)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*2402 allele.

From €105.00*
Details
EBV LMP2 200-208 (HLA-B*40:01) ( IEDPPFNSL )
IEDPPFNSL is a linear peptidic epitope (epitope ID 25756) studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*
Details
EBV LMP2 356-364 (HLA-A*02:01) ( FLYALALLL )
Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL) for stimulation of human EBV LMP2(356-364)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. LYALALLL is a linear peptidic epitope studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus).

From €105.00*
Details
EBV LMP2 419-427 mutant 426S (HLA-A*24:02) ( TYGPVFMSL )
The peptide EBV LMP2 419-427 with the amino acid sequence TYGPVFMSL is a linear epitope (epitope ID 67350) that is studied as part of Latent membrane protein 2 (UniProt:P13285) from Epstein Barr virus/Human herpesvirus 4.

From €105.00*
Details
This website uses cookies to ensure the best experience possible. More information...